Page 79 - Read Online

Page 14 of 16 Chávez-López et al. Hepatoma Res 2020;6:14 I http://dx.doi.org/10.20517/2394-5079.2019.023

60. Chandler DE, Penin F, Schulten K, Chipot C. The p7 protein of hepatitis C virus forms structurally plastic, minimalist ion channels. PLoS
Comput Biol 2012;8:e1002702.
61. Foster TL, Verow M, Wozniak AL, Bentham MJ, Thompson J, et al. Resistance mutations define specific antiviral effects for inhibitors of
the hepatitis C virus p7 ion channel. Hepatology 2011;54:79-90.
62. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious
virus. J Virol 2007;81:8374-83.
63. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, et al. Hepatitis C virus p7 protein is crucial for assembly and release of
infectious virions. PLoS Pathog 2007;3:e103.
64. Wozniak AL, Griffin S, Rowlands D, Harris M, Yi M, et al. Intracellular proton conductance of the hepatitis C virus p7 protein and its
contribution to infectious virus production. PLoS Pathog 2010;6:e1001087.
65. Griffin S, Stgelais C, Owsianka AM, Patel AH, Rowlands D, et al. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the
p7 ion channel. Hepatology 2008;48:1779-90.
66. Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, et al. Antiviral effects of amantadine and iminosugar derivatives against
hepatitis C virus. Hepatology 2007;46:330-8.
67. Shiryaev VA, Radchenko EV, Palyulin VA, Zefirov NS, Bormotov NI, et al. Molecular design, synthesis and biological evaluation of cage
compound-based inhibitors of hepatitis C virus p7 ion channels. Eur J Med Chem 2018;158:214-35.
68. Pietschmann T. Clinically approved ion channel inhibitors close gates for hepatitis C virus and open doors for drug repurposing in
infectious viral diseases. J Virol 2017;91.
69. Breitinger U, Farag NS, Ali NKM, Breitinger HA. Patch-clamp study of hepatitis C p7 channels reveals genotype-specific sensitivity to
inhibitors. Biophy J 2016;110:2419-29.
70. Hong W, Lang Y, Li T, Zeng Z, Song Y, et al. A p7 ion channel-derived peptide inhibits hepatitis C virus infection in vitro. J Biol Chem
2015;290:23254-63.
71. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwek RA, et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited
by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A 2003;100:6104-8.
72. Manzoor S, Idrees M, Ashraf J, Mehmood A, Butt S, et al. Identification of ionotrophic purinergic receptors in Huh-7 cells and their
response towards structural proteins of HCV genotype 3a. Virol J 2011;8:431.
73. Manzoor S, Akhtar U, Naseem S, Khalid M, Mazhar M, et al. Ionotropic purinergic receptors P2X4 and P2X7: proviral or antiviral? An
insight into P2X receptor signaling and hepatitis C virus infection. Viral Immunol 2016;29:401-8.
74. Sidorkiewicz M, Brocka M, Bronis M, Grek M, Jozwiak B, et al. The altered expression of alpha1 and beta3 subunits of the gamma-
aminobutyric acid A receptor is related to the hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 2012;31:1537-42.
75. Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an
open question. World J Gastroenterol 2015;21:4103-10.
76. Kikuchi L, Oliveira CP, Carrilho FJ. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Biomed Res Int 2014;2014:106247.
77. Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: an increasing concern. Indian J
Med Res 2019;149:9-17.
78. Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol
2010;3:385-96.
79. Freise C, Heldwein S, Erben U, Hoyer J, Kohler R, et al. K -channel inhibition reduces portal perfusion pressure in fibrotic rats and
+
fibrosis associated characteristics of hepatic stellate cells. Liver Int 2015;35:1244-52.
80. Paka L, Smith DE, Jung D, McCormack S, Zhou P, et al. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor,
Senicapoc, in non-alcoholic liver disease. World J Gastroenterol 2017;23:4181-90.
81. Blasetti Fantauzzi C, Menini S, Iacobini C, Rossi C, Santini E, et al. Deficiency of the purinergic receptor 2X7 attenuates nonalcoholic
steatohepatitis induced by high-fat diet: possible role of the NLRP3 inflammasome. Oxid Med Cell Longev 2017;2017:8962458.
82. Shang Y, Li XF, Jin MJ, Li Y, Wu YL, et al. Leucodin attenuates inflammatory response in macrophages and lipid accumulation in
steatotic hepatocytes via P2x7 receptor pathway: a potential role in alcoholic liver disease. Biomed Pharmacother 2018;107:374-81.
83. Huang C, Yu W, Cui H, Wang Y, Zhang L, et al. P2X7 blockade attenuates mouse liver fibrosis. Mol Med Rep 2014;9:57-62.
84. Wilson CH, Ali ES, Scrimgeour N, Martin AM, Hua J, et al. Steatosis inhibits liver cell store-operated Ca entry and reduces ER Ca
2+
2+
through a protein kinase C-dependent mechanism. Biochem J 2015;466:379-90.
85. Grimm C, Holdt LM, Chen CC, Hassan S, Muller C, et al. High susceptibility to fatty liver disease in two-pore channel 2-deficient mice.
Nat Commun 2014;5:4699.
86. Li Q, Li L, Wang F, Chen J, Zhao Y, et al. Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential
vanilloid 1-mediated peroxisome proliferator-activated receptor delta activation. Pflugers Arch 2013;465:1303-16.
87. Li L, Chen J, Ni Y, Feng X, Zhao Z, et al. TRPV1 activation prevents nonalcoholic fatty liver through UCP2 upregulation in mice.
Pflugers Arch 2012;463:727-32.
88. Zhan L, Li J. The role of TRPV4 in fibrosis. Gene 2018;642:1-8.
89. Iyer SC, Kannan A, Gopal A, Devaraj N, Halagowder D. Receptor channel TRPC6 orchestrate the activation of human hepatic stellate
cell under hypoxia condition. Exp Cell Res 2015;336:66-75.
90. Fang L, Zhan S, Huang C, Cheng X, Lv X, et al. TRPM7 channel regulates PDGF-BB-induced proliferation of hepatic stellate cells via
PI3K and ERK pathways. Toxicol Appl Pharmacol 2013;272:713-25.
91. Pan CX, Wu FR, Wang XY, Tang J, Gao WF, et al. Inhibition of ASICs reduces rat hepatic stellate cells activity and liver fibrosis: an in